Skip to Content
Merck

S0942

Phosphatase substrate

chromogenic, tablet (round)

Synonym(s):

4-Nitrophenyl phosphate disodium salt hexahydrate, pNPP disodium salt hexahydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(2)

About This Item

Linear Formula:
O2NC6H4OP(O)(ONa)2 · 6H2O
CAS Number:
333338-18-4
Molecular Weight:
371.14
NACRES:
NA.54
PubChem Substance ID:
24899454
UNSPSC Code:
12352204
EC Number:
224-246-5
MDL number:
MFCD00066288

Product Name

Phosphatase substrate, 5 mg tablets

InChI key

KAKKHKRHCKCAGH-UHFFFAOYSA-L

InChI

1S/C6H6NO6P.2Na.6H2O/c8-7(9)5-1-3-6(4-2-5)13-14(10,11)12;;;;;;;;/h1-4H,(H2,10,11,12);;;6*1H2/q;2*+1;;;;;;/p-2

SMILES string

O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)c1ccc(OP([O-])([O-])=O)cc1

form

tablet (round)

storage temp.

−20°C

Quality Level

300

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Chromogenic substrate for use with alkaline and acid phosphatase ELISA procedures. Produces a soluble end product that is yellow in color and can be read spectrophotometrically at 405 nm. The pNPP reaction may be stopped with 3 N NaOH and read at 405 nm.

General description

Substrate for the determination of acid and alkaline phosphatase

Other Notes

Substrate for the determination of acid and alkaline phosphatases.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000504713
0000504713
0000487288
0000487288
0000484192

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Thomas F Rogers et al.
Science (New York, N.Y.), 369(6506), 956-963 (2020-06-17)
Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline
Yeon-Suk Yang et al.
Molecular therapy. Methods & clinical development, 17, 922-935 (2020-05-15)
Improper activity of bone-resorbing osteoclasts results in low bone density and deterioration of bone structure, which increase the risk of fractures. Anti-resorptive therapies targeting osteoclasts have proven effective in preserving bone mass, but these therapeutic agents lead to defective new
Lijun Wang et al.
Nature communications, 11(1), 282-282 (2020-01-17)
Wolff's law and the Utah Paradigm of skeletal physiology state that bone architecture adapts to mechanical loads. These models predict the existence of a mechanostat that links strain induced by mechanical forces to skeletal remodeling. However, how the mechanostat influences
Christina Papista et al.
Kidney international, 88(2), 276-285 (2015-03-26)
IgA1 complexes containing deglycosylated IgA1, IgG autoantibodies, and a soluble form of the IgA receptor (sCD89), are hallmarks of IgA nephropathy (IgAN). Food antigens, notably gluten, are associated with increased mucosal response and IgAN onset, but their implication in the
Hanlin Zhang et al.
Molecular cell, 76(1), 110-125 (2019-09-03)
Failure to make adaptive immune responses is a hallmark of aging. Reduced B cell function leads to poor vaccination efficacy and a high prevalence of infections in the elderly. Here we show that reduced autophagy is a central molecular mechanism
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service